Delcath Systems Reports Strong Preliminary Q4/FY25 Results, Positive Cash Flow, and $6M Share Buyback

summarizeResumen

Delcath Systems announced robust preliminary financial and operational results for the fourth quarter and full year 2025. The company achieved positive operating cash flow for Q4 and significantly increased its cash and short-term investments to $91.0 million with no debt. A substantial $6.0 million share buyback demonstrates management's confidence in the company's valuation. Furthermore, the 140% growth in HEPZATO procedure volume highlights strong commercial traction for its key product. These results indicate a solid financial position and strong operational momentum, which are positive signals for investors.

check_boxEventos clave

• Strong Preliminary Financial Results

  The company reported preliminary total revenue of approximately $20.7 million for Q4 2025 and $85.2 million for the full year 2025, with HEPZATO KIT revenue reaching $19.0 million and $78.8 million for the respective periods.

• Positive Operating Cash Flow and Healthy Cash Position

  Delcath achieved positive operating cash for the fourth quarter ended December 31, 2025, and increased its cash and short-term investments to $91.0 million, up from $88.9 million as of September 30, 2025, with no outstanding debt.

• Significant Share Buyback Program

  The company repurchased 628,572 shares of common stock for $6.0 million through December 31, 2025, under its approved $25.0 million Share Buyback Program, signaling management's confidence in the company's value.

• Operational Growth in HEPZATO KIT Utilization

  Delcath reported 25 active sites utilizing HEPZATO KIT and approximately 140% growth in HEPZATO procedure volume in 2025 compared to 2024, indicating strong commercial adoption.

auto_awesomeAnalisis

Delcath Systems announced robust preliminary financial and operational results for the fourth quarter and full year 2025. The company achieved positive operating cash flow for Q4 and significantly increased its cash and short-term investments to $91.0 million with no debt. A substantial $6.0 million share buyback demonstrates management's confidence in the company's valuation. Furthermore, the 140% growth in HEPZATO procedure volume highlights strong commercial traction for its key product. These results indicate a solid financial position and strong operational momentum, which are positive signals for investors.